Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis in children.

Non-alcoholic steatohepatitis (NASH) is an important liver disease in children; it can cause cirrhosis in children. The disease mechanism involves hepatic insulin resistance with hyperinsulinemia and changes in certain adipocytokines and inflammatory mediators. The differential diagnosis of childhood NASH includes metabolic disorders, drug hepatotoxicity, and alcoholic hepatitis in adolescent p...

[Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis].

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the hepatic manifestations of the metabolic syndrome. Since the prevalence of obesity and consequently of the metabolic syndrome is steadily increasing, the different types of NAFLD are nowadays the most common cause of liver injury in North America. The development of NASH and fatty liver cirrhosis occurs af...

Immune Mechanisms in Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver had been believed to be a non-progressive benign disease. However, Ludwig et al. described some patients who exhibited progressive steatohepatitis without habitual alcohol drinking (Ludwig et al., 1980) and referred to this disease as non-alcoholic steatohepatitis (NASH). Later, NASH and non-progressive simple steatosis patients were included in the single disease enti...

Conophylline inhibits non-alcoholic steatohepatitis in mice

Conophylline (CnP), a vinca alkaloid extracted from the leaves of the tropical plant Ervatamia microphylla, attenuates hepatic fibrosis in mice. However, little is known about whether CnP inhibits steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH) in mice. A methionine-choline-deficient (MCD) diet was administered to male db/db mice as a NASH model, and CnP (1 μg/kg/d...